


We claim:

1. A method of inhibiting ERK-2 activity in a patient, which method comprises administering to said patient a compound of formula I:



or a pharmaceutically acceptable derivative thereof, wherein:

Sp is a spacer group comprising a 5-membered heteroaromatic ring, wherein Ring A and QR² are attached to Sp at non-adjacent positions; and wherein Sp has up to two R⁶ substituents, provided that two substitutable carbon ring atoms in Sp are not simultaneously substituted by R⁶;

Z¹ and Z² are each independently selected from N or CH;

T and Q are each an independently selected linker group;

U is selected from -NR⁷-, -NR⁷CO-, -NR⁷CONR⁷-, -NR⁷CO₂-, -O-, -CONR⁷-, -CO-, -CO₂-, -OC(O)-, -NR⁷SO₂-, -SO₂NR⁷-, -NR⁷SO₂NR⁷-, or -SO₂-;

m and n are each independently selected from zero or one;

R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR, or OH;

R² is selected from -(CH₂)_yR⁵, -(CH₂)_yCH(R⁵)₂, -(CH₂)_yCH(R⁸)CH(R⁵)₂, -N(R⁴)₂, or -NR⁴(CH₂)_yN(R⁴)₂;

y is 0-6;

20071699-020602


Sub
A1

Sub A1

208220-66974007

R^3 is selected from R^7 , R , $-(CH_2)_yCH(R^8)R$, CN ,
 $-(CH_2)_yCH(R^8)CH(R^5)_2$, or $-(CH_2)_yCH(R^8)N(R^4)_2$;
each R is independently selected from an optionally
substituted group selected from C_{1-6} aliphatic, C_{6-10}
aryl, a heteroaryl ring having 5-10 ring atoms, or a
heterocyclyl ring having 3-10 ring atoms;
each R^4 is independently selected from R , R^7 , $-COR^7$, $-CO_2R$,
 $-CON(R^7)_2$, $-SO_2R^7$, $-(CH_2)_yR^5$, or $-(CH_2)_yCH(R^5)_2$;
each R^5 is independently selected from R , OR , CO_2R ,
 $(CH_2)_yN(R^7)_2$, $N(R^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $NR^7CON(R^7)_2$,
 $CON(R^7)_2$, SO_2R^7 , $NR^7SO_2R^7$, COR^7 , CN , or $SO_2N(R^7)_2$;
each R^6 is independently selected from R^7 , F , Cl ,
 $(CH_2)_yN(R^7)_2$, $N(R^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $NR^7CON(R^7)_2$,
 $CON(R^7)_2$, SO_2R^7 , $NR^7SO_2R^7$, COR^7 , CN , or $SO_2N(R^7)_2$;
each R^7 is independently selected from hydrogen or an
optionally substituted C_{1-6} aliphatic group, or two R^7
on the same nitrogen are taken together with the
nitrogen to form a 5-8 membered heterocyclyl or
heteroaryl ring;
 R^8 is selected from R , $(CH_2)_wOR^7$, $(CH_2)_wN(R^4)_2$, or $(CH_2)_wSR^7$;
and
each w is independently selected from 0-4.

2. The method according to claim 1, wherein Sp is
selected from one of the following:



or a pharmaceutically acceptable derivative thereof.

3. The method according to claim 2, wherein said compound has one or more features selected from the group consisting of:

- 5ub
A1
- 10071699.020802
- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
 - (b) $T_m R^1$ is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
 - (c) Q is $-\text{CO}-$, $-\text{CO}_2-$, $-\text{CONH}-$, $-\text{SO}_2-$, $-\text{SO}_2\text{NH}-$, $-\text{OC(O)NH}-$, $-\text{C(O)ONH}-$, or $-\text{CONHNH}-$;
 - (d) R^2 is $-\text{NR}^4(\text{CH}_2)_y\text{N}(\text{R}^4)_2$, $-(\text{CH}_2)_y\text{R}^5$, $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$, or $-(\text{CH}_2)_y\text{CH}(\text{R}^8)\text{CH}(\text{R}^5)_2$;
 - (f) R^4 is R, R^7 , or $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$; and
 - (g) R^5 is an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

4. The method according to claim 3, wherein:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) $T_m R^1$ is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-\text{CO}-$, $-\text{CO}_2-$, $-\text{CONH}-$, $-\text{SO}_2-$, $-\text{SO}_2\text{NH}-$, $-\text{OC(O)NH}-$, $-\text{C(O)ONH}-$, or $-\text{CONHNH}-$;

- (d) R^2 is $-NR^4(CH_2)_yN(R^4)_2$, $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$;
- (f) R^4 is R, R^7 , or $-(CH_2)_yCH(R^5)_2$; and
- (g) R^5 is an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

5. The method according to claim 3, wherein said compound has one or more features selected from the group consisting of:


- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-CH(CH_2OH)phenyl$, $-CH(CH_2OH)ethyl$, $-CH(CH_2OH)_2$, $-CH(CH_2OH)isopropyl$, $-CH(CH_2OH)CH_2cyclopropyl$, or an optionally substituted phenyl, benzyl, or isoxazolyl group;
- (b) T_mR^1 is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, or CH_2NHCH_3 ;
- (c) Q is $-CO-$, $-CONH-$, $-SO_2-$, or $-SO_2NH-$;
- (d) R^2 is $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$, wherein R^8 is OH or CH_2OH ; and
- (e) R^5 is $-CH_2OH$, $-(CH_2)_2OH$, isopropyl, or an optionally substituted group selected from pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, or benzyl.

20071699-020802

Sub
A1

6. The method according to claim 5, wherein:
- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-\text{CH}(\text{CH}_2\text{OH})\text{phenyl}$, $-\text{CH}(\text{CH}_2\text{OH})\text{ethyl}$, $-\text{CH}(\text{CH}_2\text{OH})_2$, $-\text{CH}(\text{CH}_2\text{OH})\text{isopropyl}$, $-\text{CH}(\text{CH}_2\text{OH})\text{CH}_2\text{cyclopropyl}$, or an optionally substituted phenyl, benzyl, or isoxazolyl group;
 - (b) $T_m R^1$ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH , NH_2 , NHCH_3 , NHAc , $\text{NHC}(\text{O})\text{NHCH}_3$, or CH_2NHCH_3 ;
 - (c) Q is $-\text{CO}-$, $-\text{CONH}-$, $-\text{SO}_2-$, or $-\text{SO}_2\text{NH}-$;
 - (d) R^2 is $-(\text{CH}_2)_y R^5$, $-(\text{CH}_2)_y \text{CH}(R^5)_2$, or $-(\text{CH}_2)_y \text{CH}(R^8) \text{CH}(R^5)_2$, wherein R^8 is OH or CH_2OH ; and
 - (e) R^5 is $-\text{CH}_2\text{OH}$, $-(\text{CH}_2)_2\text{OH}$, isopropyl, or an optionally substituted group selected from pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, or benzyl.

7. The method according to claim 2, wherein said compound is of formula III-a:



III-a

Sub
A1

10071699-020802

or a pharmaceutically acceptable derivative thereof.

8. The method according to claim 7, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) $T_m R^1$ is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-\text{CO}-$, $-\text{CO}_2-$, $-\text{CONH}-$, $-\text{SO}_2-$, $-\text{SO}_2\text{NH}-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{ONH}-$, or $-\text{CONHNH}-$;
- (d) R^2 is $-\text{NR}^4(\text{CH}_2)_y\text{N}(R^4)_2$, $-(\text{CH}_2)_yR^5$, $-(\text{CH}_2)_y\text{CH}(R^5)_2$, or $-(\text{CH}_2)_y\text{CH}(R^8)\text{CH}(R^5)_2$;
- (f) R^4 is R, R^7 , or $-(\text{CH}_2)_y\text{CH}(R^5)_2$; and
- (g) R^5 is an optionally substituted group selected from phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

9. The method according to claim 8, wherein:


- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) $T_m R^1$ is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;

Sub
A1

10071699.020802

- (c) Q is -CO-, -CO₂-, -CONH-, -SO₂-, -SO₂NH-,
-OC(O)NH-, -C(O)ONH-, or -CONHNH-;
- (d) R² is -NR⁴(CH₂)_yN(R⁴)₂, -(CH₂)_yR⁵, -(CH₂)_yCH(R⁵)₂, or
-(CH₂)_yCH(R⁸)CH(R⁵)₂;
- (f) R⁴ is R, R⁷, or -(CH₂)_yCH(R⁵)₂; and
- (g) R⁵ is an optionally substituted group selected
from phenyl, 5-6 membered heteroaryl, or 5-6
membered heterocyclyl.

10. A method of inhibiting ERK-2 activity in a
biological sample, which method comprises contacting said
sample with a compound of formula I:



or a pharmaceutically acceptable derivative thereof,
wherein:

Sp is a spacer group comprising a 5-membered
heteroaromatic ring, wherein Ring A and QR² are
attached to Sp at non-adjacent positions; and wherein
Sp has up to two R⁶ substituents, provided that two
substitutable carbon ring atoms in Sp are not
simultaneously substituted by R⁶;

Z¹ and Z² are each independently selected from N or CH;

T and Q are each an independently selected linker group;

U is selected from -NR⁷-, -NR⁷CO-, -NR⁷CONR⁷-, -NR⁷CO₂-,
-O-, -CONR⁷-, -CO-, -CO₂-, -OC(O)-, -NR⁷SO₂-, -SO₂NR⁷-,
-NR⁷SO₂NR⁷-, or -SO₂-;

10071699.020802


Sub
A1

Sub
A1

10071699-020802

m and n are each independently selected from zero or one;
R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR,
or OH;
R² is selected from -(CH₂)_yR⁵, -(CH₂)_yCH(R⁵)₂,
-(CH₂)_yCH(R⁸)CH(R⁵)₂, -N(R⁴)₂, or -NR⁴(CH₂)_yN(R⁴)₂;
y is 0-6;
R³ is selected from R⁷, R, -(CH₂)_yCH(R⁸)R, CN,
-(CH₂)_yCH(R⁸)CH(R⁵)₂, or -(CH₂)_yCH(R⁸)N(R⁴)₂;
each R is independently selected from an optionally
substituted group selected from C₁₋₆ aliphatic, C₆₋₁₀
aryl, a heteroaryl ring having 5-10 ring atoms, or a
heterocyclyl ring having 3-10 ring atoms;
each R⁴ is independently selected from R, R⁷, -COR⁷, -CO₂R,
-CON(R⁷)₂, -SO₂R⁷, -(CH₂)_yR⁵, or -(CH₂)_yCH(R⁵)₂;
each R⁵ is independently selected from R, OR, CO₂R,
(CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,
CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;
each R⁶ is independently selected from R⁷, F, Cl,
(CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,
CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;
each R⁷ is independently selected from hydrogen or an
optionally substituted C₁₋₆ aliphatic group, or two R⁷
on the same nitrogen are taken together with the
nitrogen to form a 5-8 membered heterocyclyl or
heteroaryl ring;
R⁸ is selected from R, (CH₂)_wOR⁷, (CH₂)_wN(R⁴)₂, or (CH₂)_wSR⁷;
and
each w is independently selected from 0-4.

11. The method according to claim 10, wherein Sp is
selected from one of the following:



or a pharmaceutically acceptable derivative thereof.

12. The method according to claim 11, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) $T_m R^1$ is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-CO-$, $-CO_2-$, $-CONH-$, $-SO_2-$, $-SO_2NH-$, $-OC(O)NH-$, $-C(O)ONH-$, or $-CONHNH-$;
- (d) R^2 is $-NR^4(CH_2)_yN(R^4)_2$, $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$;
- (f) R^4 is R, R^7 , or $-(CH_2)_yCH(R^5)_2$; and
- (g) R^5 is an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

13. The method according to claim 12, wherein:

- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4}

Sub
A'

10071699-020802

aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;

- (b) $T_m R^1$ is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-CO-$, $-CO_2-$, $-CONH-$, $-SO_2-$, $-SO_2NH-$, $-OC(O)NH-$, $-C(O)ONH-$, or $-CONHNH-$;
- (d) R^2 is $-NR^4(CH_2)_yN(R^4)_2$, $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$;
- (f) R^4 is R, R^7 , or $-(CH_2)_yCH(R^5)_2$; and
- (g) R^5 is an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

14. The method according to claim 12, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-CH(CH_2OH)phenyl$, $-CH(CH_2OH)ethyl$, $-CH(CH_2OH)_2$, $-CH(CH_2OH)isopropyl$, $-CH(CH_2OH)CH_2cyclopropyl$, or an optionally substituted phenyl, benzyl, or isoxazolyl group;
- (b) $T_m R^1$ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, or CH_2NHCH_3 ;
- (c) Q is $-CO-$, $-CONH-$, $-SO_2-$, or $-SO_2NH-$;
- (d) R^2 is $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$, wherein R^8 is OH or CH_2OH ; and

10071699.020802

Sub
A1


- Sub
Al
- (e) R^5 is $-CH_2OH$, $-(CH_2)_2OH$, isopropyl, or an optionally substituted group selected from pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, or benzyl.

15. The method according to claim 14, wherein:

- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-CH(CH_2OH)$ phenyl, $-CH(CH_2OH)$ ethyl, $-CH(CH_2OH)_2$, $-CH(CH_2OH)$ isopropyl, $-CH(CH_2OH)CH_2$ cyclopropyl, or an optionally substituted phenyl, benzyl, or isoxazolyl group;
- (b) T_mR^1 is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, or CH_2NHCH_3 ;
- (c) Q is $-CO-$, $-CONH-$, $-SO_2-$, or $-SO_2NH-$;
- (d) R^2 is $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$, wherein R^8 is OH or CH_2OH ; and
- (e) R^5 is $-CH_2OH$, $-(CH_2)_2OH$, isopropyl, or an optionally substituted group selected from pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, or benzyl.

208020-66974007

16. The method according to claim 11, wherein said compound is of formula III-a:



III-a

or a pharmaceutically acceptable derivative thereof.

17. The method according to claim 16, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-CO-$, $-CO_2-$, $-CONH-$, $-SO_2-$, $-SO_2NH-$, $-OC(O)NH-$, $-C(O)ONH-$, or $-CONHNH-$;
- (d) R^2 is $-NR^4(CH_2)_yN(R^4)_2$, $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$;
- (f) R^4 is R, R^7 , or $-(CH_2)_yCH(R^5)_2$; and
- (g) R^5 is an optionally substituted group selected from phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

18. The method according to claim 17, wherein:

Sub
A1

10071699-020802

- Sub
A1
- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)\text{R}$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $\text{N}(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-\text{CO}-$, $-\text{CO}_2-$, $-\text{CONH}-$, $-\text{SO}_2-$, $-\text{SO}_2\text{NH}-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{ONH}-$, or $-\text{CONHNH}-$;
- (d) R^2 is $-\text{NR}^4(\text{CH}_2)_y\text{N}(R^4)_2$, $-(\text{CH}_2)_y\text{R}^5$; $-(\text{CH}_2)_y\text{CH}(R^5)_2$, or $-(\text{CH}_2)_y\text{CH}(R^8)\text{CH}(R^5)_2$;
- (f) R^4 is R, R^7 , or $-(\text{CH}_2)_y\text{CH}(R^5)_2$; and
- (g) R^5 is an optionally substituted group selected from phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

19. A method of inhibiting ERK-2 activity in a patient, which method comprises administering to said patient a compound selected from the group consisting of:

4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid dimethylamide;
{4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-pyrrolidin-1-yl-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-pyrrolidin-1-yl-methanone;
4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-morpholin-4-yl-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[1,4']bipiperidinyl-1'-yl-methanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3-hydroxy-piperidin-1-yl)-methanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[1,4']bipiperidinyl-1'-yl-methanone;
[4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[1,4']bipiperidinyl-1'-yl-methanone;

20071699.020802

{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[1,4']bipiperidinyl-1'-yl-methanone;
[4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-hydroxy-piperidin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-(2-fluoro-phenyl)-piperazin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-phenyl-piperazin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-pyridin-2-yl-piperazin-1-yl)-methanone;
[4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-morpholin-4-yl-methanone;
4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;
[4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-morpholin-4-yl-methanone;
4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;
4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-(4-phenyl-piperazin-1-yl)-methanone;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-(4-pyridin-2-yl-piperazin-1-yl)-methanone;
[4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-morpholin-4-yl-methanone;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-(4-hydroxy-piperidin-1-yl)-methanone;
[4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl]-[1,4']bipiperidinyl-1'-yl-methanone;
4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-(4-methoxy-phenyl)-piperazin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(2-hydroxymethyl-piperidin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;

Sub
A1

10071699-020802

4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;
4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(4-phenyl-piperazin-1-yl)-methanone;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;
4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;
{4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;
4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;
{4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[2-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-phenyl-piperazin-1-yl)-methanone;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(4-(2-fluoro-phenyl)-piperazin-1-yl)-methanone;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(3-hydroxy-piperidin-1-yl)-methanone;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(4-(4-methoxy-phenyl)-piperazin-1-yl)-methanone;
{4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl}-(4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl)-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;
1-(4-{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carbonyl}-piperazin-1-yl)-ethanone;

Sub
A1

10071699 020802

Sub
A1

10071699-020802

{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;
{4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3-hydroxy-piperidin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-methyl-[1,4]diazepan-1-yl)-methanone;
1-{4-[4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carbonyl]-piperazin-1-yl}-ethanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(3-hydroxy-piperidin-1-yl)-methanone;
4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid methyl-(2-pyridin-2-yl-ethyl)-amide;
[4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[2-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[2-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone;
4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-pyridin-2-yl-piperazin-1-yl)-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-hydroxy-piperidin-1-yl)-methanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-hydroxy-piperidin-1-yl)-methanone;
{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-hydroxy-piperidin-1-yl)-methanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-pyridin-2-yl-piperazin-1-yl)-methanone;
{4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-methanone;
1-{4-[4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrole-2-carbonyl]-piperazin-1-yl}-ethanone;
{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
[4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-pyrrolidin-1-yl-methanone;
{4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-morpholin-4-yl-methanone;

4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzylamide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 4-fluoro-benzylamide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-benzylamide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 4-methoxy-benzylamide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;
4-(2,5-Diamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(5-Acetylamino-2-amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-[2-Amino-5-(3-methyl-ureido)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-hydroxy-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-methylaminomethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-[2-Cyclohexylamino-5-(3-methyl-ureido)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-[2-Acetylamino-5-(3-methyl-ureido)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4--(5-Hydroxy-2-methanesulfonylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-methanesulfonyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;
4-(2-Amino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide;

Sub
Al

10071699.020802

4-(2-Cyclohexylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (pyridin-4-ylmethyl)-amide;

4-[5-(3,5-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-trifluoromethyl-benzylamide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-dimethylamino-2-pyridin-3-yl-ethyl)-amide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 4-methanesulfonyl-benzylamide;

4-[5-(3,5-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;

4-[5-(3,5-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-2-pyridin-3-yl-ethyl)-amide;

4-[2-Amino-5-(3-fluoro-5-trifluoromethyl-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Amino-5-propyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

4-(2-Methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-dimethylamino-ethyl)-amide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid propylamide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-phenyl-propyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (naphthalen-1-ylmethyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid cyclopropylamide;

4-(2-Ethylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 2-trifluoromethyl-benzylamide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

Sub
A1

10071699.020802

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Ethylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (4-methyl-cyclohexyl)-amide;
4-(5-Ethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid isopropylamide;
4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-amino-ethyl)-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;
1-{4-[4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carbonyl]-piperazin-1-yl}-ethanone;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-phenyl-propyl)-amide;
4-(2-Amino-5-ethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-(6-methoxy-1H-indol-3-yl)-ethyl]-amide;
4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-phenoxy-ethyl)-amide;
4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1-methyl-3-phenyl-propyl)-amide;
4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide;
4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1-hydroxymethyl-3-methyl-butyl)-amide;
4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-hydroxymethyl-2-(1H-imidazol-4-yl)-ethyl]-amide;
4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide;
4-[2-(2-Diethylamino-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3,4-difluorobenzylamide;
4-[5-Methyl-2-(2-piperidin-1-yl-quinazolin-4-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzylamide;
4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-4-fluoro-phenyl)-2-hydroxy-ethyl]-amide;
4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-4-fluoro-phenyl)-2-hydroxy-ethyl]-amide;
4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(3-Methoxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

Sub
A1

10071699.020802

4- [2- (3-Hydroxy-phenylamino) -5-methyl-pyrimidin-4-yl] -
1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -
amide;

4- [2- (Benzo [1,3]dioxol-5-ylamino) -5-methyl-pyrimidin-4-
yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl) -amide;

4- [5-Methyl-2- (4-sulfamoyl-phenylamino) -pyrimidin-4-
yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl) -amide;

4- [2- (3-Benzyloxy-phenylamino) -5-methyl-pyrimidin-4-
yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl) -amide;

4- [2- (4-Hydroxy-cyclohexylamino) -5-methyl-pyrimidin-4-
yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl) -amide;

4- (5-Cyclohexyl-2-phenylamino-pyrimidin-4-yl) -1H-
pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -
amide;

4- (5-Cyclopropyl-2-phenylamino-pyrimidin-4-yl) -1H-
pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -
amide;

4- (5-Methyl-2-phenylamino-pyrimidin-4-yl) -1H-pyrrole-2-
carboxylic acid [1- (3-fluoro-4-methyl-phenyl) -2-hydroxy-
ethyl] -amide;

4- (5-Methyl-2-phenylamino-pyrimidin-4-yl) -1H-pyrrole-2-
carboxylic acid [2-hydroxy-1- (3-trifluoromethyl-phenyl) -
ethyl] -amide;

4- [2- (3-Fluoro-phenylamino) -5-methyl-pyrimidin-4-yl] -
1H-pyrrole-2-carboxylic acid [1- (3-fluoro-4-methyl-
phenyl) -2-hydroxy-ethyl] -amide;

4- [2- (3-Fluoro-phenylamino) -5-methyl-pyrimidin-4-yl] -
1H-pyrrole-2-carboxylic acid [2-hydroxy-1- (3-
trifluoromethyl-phenyl) -ethyl] -amide;

4- [5-Methyl-2- (3-trifluoromethyl-phenylamino) -
pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-
1-phenyl-ethyl) -amide;

4- (2-Benzylamino-5-methyl-pyrimidin-4-yl) -1H-pyrrole-2-
carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4- [2- (3,4-Dimethyl-phenylamino) -5-methyl-pyrimidin-4-
yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl) -amide;

4- [2- (4-Benzyloxy-phenylamino) -5-methyl-pyrimidin-4-
yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl) -amide;

4- (2-Isopropylamino-5-methyl-pyrimidin-4-yl) -1H-
pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -
amide;

Sub
A1

10071699.020802

4- [5-Methyl-2- (2,2,2-trifluoro-ethylamino) -pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- [2- (2-Hydroxy-1-phenyl-ethylamino) -5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- [2- (2-Methoxy-phenylamino) -5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- [5-Methyl-2- (4-trifluoromethoxy-phenylamino) -pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- (2-Isobutylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- [2- (Cyclopropylmethyl-amino) -5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- (5-Methoxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- (2-Amino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- (2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- (5-Methyl-2-propylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- [2- (2-Hydroxy-1-phenyl-ethylamino) -5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4- (2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

4- (2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

4- (2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-2-phenyl-ethyl)-methyl-amide;

4- (2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

4- (2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

4- (2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-2-phenyl-ethyl)-amide;

4- (2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

4- (2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-hydroxymethyl-2-phenyl-ethyl)-amide;

Sub
Al
10071699.020802
20080206 66974007

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-hydroxymethyl-2-phenyl-ethyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

4-[2-(1-Hydroxymethyl-cyclopropylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(2-Hydroxy-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(2-Hydroxy-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(2-Hydroxy-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(2-Hydroxy-cyclohexylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Hydroxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

{[4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carbonyl]-amino}-phenyl-acetic acid methyl ester;

4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

4-(2-Ethylamino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-pyridin-3-yl-ethyl)-amide;

4-(2-Ethylamino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

Sub
A1

10071699-020802

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-ethyl]-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(2-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(2-Cyclopropyl-1-hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(2,3-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Ethoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(1-Hydroxymethyl-2-methyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-oxo-1-phenyl-propyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-[2-(2-Chloro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(2-methoxy-phenyl)-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

10071699-020802

Sub
A1

4-(2-Methoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Isopropoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2-Chloro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2,3-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-(2-Acetylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[5-Methyl-2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-{5-Methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-{5-Methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

N'-{4-[5-(2-Hydroxy-1-phenyl-ethylcarbamoyl)-1H-pyrrol-3-yl]-5-methyl-pyrimidin-2-yl}-hydrazinecarboxylic acid ethyl ester;

4-{5-Methyl-2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Cyclopropylmethoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(Isoxazol-3-ylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Cyanoamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

Sub
A1

10071699-020802

4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(2-Hydroxy-ethoxyamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(N',N'-Dimethyl-hydrazino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[5-Methyl-2-(2-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[5-Methyl-2-(morpholin-4-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[5-Methyl-2-(5-methyl-isoxazol-3-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-{2-[1-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-5-methyl-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(2-Hydroxy-1-hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2-Hydroxy-1-hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;


4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide; and

4-[5-Methyl-2-(2-methyl-cyclopropylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide.

Sub
A

10071699.020802

20. A compound of formula I' :



or a pharmaceutically acceptable derivative thereof,
wherein:

Sp is a spacer group comprising a 5-membered
heteroaromatic ring, wherein Ring A and Q'R² are
attached to Sp at non-adjacent positions; and wherein
Sp has up to two R⁶ substituents, provided that two
substitutable carbon ring atoms in Sp are not
simultaneously substituted by R⁶;

Z¹ and Z² are each independently selected from N or CH;

T is a linker group;

Q' is selected from -CO₂-, -C(O)NR⁷- or -SO₂NR⁷-;

U is selected from -NR⁷-, -NR⁷CO-, -NR⁷CONR⁷-, -NR⁷CO₂-,
-O-, -CONR⁷-, -CO-, -CO₂-, -OC(O)-, -NR⁷SO₂-, -SO₂NR⁷-,
-NR⁷SO₂NR⁷-, or -SO₂-;

m and n are each independently selected from zero or one;

R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR,
or OH;

R²' is selected from -(CH₂)_yCH(R⁵)₂ or -(CH₂)_yCH(R⁸)CH(R⁵)₂;

y is 0-6;

R³ is selected from R⁷, R, -(CH₂)_yCH(R⁸)R, CN,


-(CH₂)_yCH(R⁸)CH(R⁵)₂, or -(CH₂)_yCH(R⁸)N(R⁴)₂;

each R is independently selected from an optionally
substituted group selected from C₁₋₆ aliphatic, C₆₋₁₀

10071699-020802

aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms;
 each R^4 is independently selected from R, R^7 , $-\text{COR}^7$, $-\text{CO}_2\text{R}$, $-\text{CON}(\text{R}^7)_2$, $-\text{SO}_2\text{R}^7$, $-(\text{CH}_2)_y\text{R}^5$, or $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$;
 each R^5 is independently selected from R, OR, CO_2R , $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SO_2R^7 , $\text{NR}^7\text{SO}_2\text{R}^7$, COR^7 , CN, or $\text{SO}_2\text{N}(\text{R}^7)_2$;
 each R^6 is independently selected from R^7 , F, Cl, $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SO_2R^7 , $\text{NR}^7\text{SO}_2\text{R}^7$, COR^7 , CN, or $\text{SO}_2\text{N}(\text{R}^7)_2$;
 each R^7 is independently selected from hydrogen or an optionally substituted C_{1-6} aliphatic group, or two R^7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
 R^8 is selected from R, $(\text{CH}_2)_w\text{OR}^7$, $(\text{CH}_2)_w\text{N}(\text{R}^4)_2$, or $(\text{CH}_2)_w\text{SR}^7$;
 and
 each w is independently selected from 0-4.

21. The compound according to claim 20, wherein Sp is selected from one of the following:



or a pharmaceutically acceptable derivative thereof.

Sub
A1

10071699.020802

22. The compound according to claim 21, wherein said compound has one or more features selected from the group consisting of:

- Sub
A1
- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)\text{R}$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
 - (b) T_mR^1 is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
 - (c) R^5 is R or OR^7 , wherein R is carbocyclic, or an optionally substituted 5 or 6-membered aryl or heteroaryl ring.

23. The compound according to claim 22, wherein:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)\text{R}$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is R or OR^7 , wherein R is carbocyclic, or an optionally substituted 5 or 6-membered aryl or heteroaryl ring.

24. The compound according to claim 22, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl,

10071699-020802

-CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂,
-CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or
an optionally substituted phenyl, benzyl, or
isoxazolyl group;

- (b) T_mR¹ is selected from optionally substituted
phenyl, methyl, ethyl, propyl, cyclopropyl,
cyclohexyl, CH₂OCH₃, CH₂OH, OH, NH₂, NHCH₃, NHAc,
NHC(O)NHCH₃, or CH₂NHCH₃; and
- (c) R⁵ is OH, CH₂OH, carbocyclic, or an optionally
substituted phenyl or pyridyl ring, and Q' is
-C(O)NH-.


25. The compound according to claim 24, wherein:

- (a) R³ is selected from hydrogen, methyl, ethyl,
propyl, cyclopropyl, cyclohexyl, isopropyl,
-CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂,
-CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or
an optionally substituted phenyl, benzyl, or
isoxazolyl group;
- (b) T_mR¹ is selected from optionally substituted
phenyl, methyl, ethyl, propyl, cyclopropyl,
cyclohexyl, CH₂OCH₃, CH₂OH, OH, NH₂, NHCH₃, NHAc,
NHC(O)NHCH₃, or CH₂NHCH₃; and
- (c) R⁵ is OH, CH₂OH, carbocyclic, or an optionally
substituted phenyl or pyridyl ring, and Q' is
-C(O)NH-.

26. The compound according to claim 21, wherein
said compound is of formula I":

20071699.020802

5. b
A1



or a pharmaceutically acceptable derivative thereof.

27. The compound according to claim 26, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is an optionally substituted 6-membered aryl, heteroaryl, or carbocyclic ring.

28. The compound according to claim 27, wherein:


- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and

Sub
A1

20071699-020802

- (c) R^5 is an optionally substituted 6-membered aryl, heteroaryl, or carbocyclic ring.

29. The compound according to claim 21, wherein said compound is of formula I°:



or a pharmaceutically acceptable derivative thereof.

30. The compound according to claim 29, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is R or OR^7 , wherein R is carbocyclic, or an optionally substituted 5 or 6-membered aryl or heteroaryl ring.

31. The compound according to claim 30, wherein:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4}


20071699-020802

aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;

(b) $T_m R^1$ is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and

(c) R^5 is R or OR^7 , wherein R is carbocyclic, or an optionally substituted 5 or 6-membered aryl or heteroaryl ring.

32. A compound of formula III-a' :



or a pharmaceutically acceptable derivative thereof, wherein:

T is a linker group;

U is selected from $-NR^7-$, $-NR^7CO-$, $-NR^7CONR^7-$, $-NR^7CO_2-$, $-O-$, $-CONR^7-$, $-CO-$, $-CO_2-$, $-OC(O)-$, $-NR^7SO_2-$, $-SO_2NR^7-$, $-NR^7SO_2NR^7-$, or $-SO_2-$;

m and n are each independently selected from zero or one;

R^1 is selected from hydrogen, CN, halogen, R, $N(R^7)_2$, OR, or OH;

R^3 is selected from R^7 , R, $-(CH_2)_yCH(R^8)R$, CN, $-(CH_2)_yCH(R^8)CH(R^5)_2$, or $-(CH_2)_yCH(R^8)N(R^4)_2$;

each R is independently selected from an optionally substituted group selected from C_{1-6} aliphatic, C_{6-10}

Sub
Al

20071699-020802

aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms;
each R^4 is independently selected from R, R^7 , $-\text{COR}^7$, $-\text{CO}_2\text{R}$, $-\text{CON}(\text{R}^7)_2$, $-\text{SO}_2\text{R}^7$, $-(\text{CH}_2)_y\text{R}^5$, or $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$;
each R^5 is independently selected from R, OR, CO_2R , $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SO_2R^7 , $\text{NR}^7\text{SO}_2\text{R}^7$, COR^7 , CN, or $\text{SO}_2\text{N}(\text{R}^7)_2$;
each R^6 is independently selected from R^7 , F, Cl, $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SO_2R^7 , $\text{NR}^7\text{SO}_2\text{R}^7$, COR^7 , CN, or $\text{SO}_2\text{N}(\text{R}^7)_2$;
each R^7 is independently selected from hydrogen or an optionally substituted C_{1-6} aliphatic group, or two R^7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
 R^8 is selected from R, $(\text{CH}_2)_w\text{OR}^7$, $(\text{CH}_2)_w\text{N}(\text{R}^4)_2$, or $(\text{CH}_2)_w\text{SR}^7$;
and
each w is independently selected from 0-4.

33. The compound according to claim 32, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(\text{R}^8)\text{R}$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $\text{N}(\text{R}^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is an optionally substituted 6-membered aryl, heteroaryl, or carbocyclic ring.

Sub
A1

10071659.020802

34. The compound according to claim 33, wherein:

- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is an optionally substituted 6-membered aryl, heteroaryl, or carbocyclic ring.

35. The compound according to claim 33, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-CH(CH_2OH)$ phenyl, $-CH(CH_2OH)$ ethyl, $-CH(CH_2OH)_2$, $-CH(CH_2OH)$ isopropyl, $-CH(CH_2OH)CH_2$ cyclopropyl, or an optionally substituted phenyl or benzyl group;
- (b) T_mR^1 is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, or CH_2NHCH_3 ; and
- (c) R^5 is cyclohexyl or an optionally substituted phenyl or pyridylring.

36. The compound according to claim 35, wherein:

- (a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-CH(CH_2OH)$ phenyl, $-CH(CH_2OH)$ ethyl, $-CH(CH_2OH)_2$, $-CH(CH_2OH)$ isopropyl, $-CH(CH_2OH)CH_2$ cyclopropyl, or

Scb
A1


10071699-020802

an optionally substituted phenyl or benzyl group;

(b) $T_m R^1$ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, or CH_2NHCH_3 ; and

(c) R^5 is cyclohexyl or an optionally substituted phenyl or pyridyl ring.

37. A compound of formula III-a°:



or a pharmaceutically acceptable derivative thereof, wherein:

T is a linker group;

U is selected from $-NR^7-$, $-NR^7CO-$, $-NR^7CONR^7-$, $-NR^7CO_2-$, $-O-$, $-CONR^7-$, $-CO-$, $-CO_2-$, $-OC(O)-$, $-NR^7SO_2-$, $-SO_2NR^7-$, $-NR^7SO_2NR^7-$, or $-SO_2-$;

m and n are each independently selected from zero or one;

R^1 is selected from hydrogen, CN, halogen, R, $N(R^7)_2$, OR, or OH;

y is 0-6;

R^3 is selected from R^7 , R, $-(CH_2)_yCH(R^8)R$, CN, $-(CH_2)_yCH(R^8)CH(R^5)_2$, or $-(CH_2)_yCH(R^8)N(R^4)_2$;

each R is independently selected from an optionally substituted group selected from C_{1-6} aliphatic, C_{6-10}

Sub
A1

10071699.020862

Sub A1
10071699.020302

aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms;
each R^4 is independently selected from R, R^7 , $-\text{COR}^7$, $-\text{CO}_2\text{R}$, $-\text{CON}(\text{R}^7)_2$, $-\text{SO}_2\text{R}^7$, $-(\text{CH}_2)_y\text{R}^5$, or $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$;
each R^5 is independently selected from R, OR, CO_2R , $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SO_2R^7 , $\text{NR}^7\text{SO}_2\text{R}^7$, COR^7 , CN, or $\text{SO}_2\text{N}(\text{R}^7)_2$;
each R^6 is independently selected from R^7 , F, Cl, $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, OR^7 , SR^7 , NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SO_2R^7 , $\text{NR}^7\text{SO}_2\text{R}^7$, COR^7 , CN, or $\text{SO}_2\text{N}(\text{R}^7)_2$;
each R^7 is independently selected from hydrogen or an optionally substituted C_{1-6} aliphatic group, or two R^7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
 R^8 is selected from R, $(\text{CH}_2)_w\text{OR}^7$, $(\text{CH}_2)_w\text{N}(\text{R}^4)_2$, or $(\text{CH}_2)_w\text{SR}^7$;
and
each w is independently selected from 0-4.

38. The compound according to claim 37, wherein said compound has one or more features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(\text{R}^8)\text{R}$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, $\text{N}(\text{R}^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is R or OR^7 , and R^8 is R^7 or OR^7 .

39. The compound according to claim 38, wherein:

- Sub
A1
- (a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) $T_m R^1$ is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is R or OR^7 , and R^8 is R^7 or OR^7 .

40. A compound selected from the group consisting of:

4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-dimethylamino-2-pyridin-3-yl-ethyl)-amide;

4-[5-(3,5-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-2-pyridin-3-yl-ethyl)-amide;

4-[2-Amino-5-(3-fluoro-5-trifluoromethyl-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1-hydroxymethyl-3-methyl-butyl)-amide;

10071699-020802

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-hydroxymethyl-2-(1H-imidazol-4-yl)-ethyl]-amide;

4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-4-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-4-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(3-Methoxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(3-Hydroxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(Benzo[1,3]dioxol-5-ylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[5-Methyl-2-(4-sulfamoyl-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(3-Benzoyloxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(4-Hydroxy-cyclohexylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Cyclohexyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Cyclopropyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-4-methyl-phenyl)-2-hydroxy-ethyl]-amide;

4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-4-methyl-phenyl)-2-hydroxy-ethyl]-amide;

4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

Sub
A1

10071699-020802

4-[5-Methyl-2-(3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Benzylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(3,4-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(4-Benzoyloxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Isopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[5-Methyl-2-(2,2,2-trifluoro-ethylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(2-Methoxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[5-Methyl-2-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Isobutylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(Cyclopropylmethyl-amino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(5-Methoxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Amino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(5-Methyl-2-propylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

Scb

A1

10071699-020802

4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid
(2-hydroxy-2-phenyl-ethyl)-methyl-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-
amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-
amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (2-hydroxy-2-phenyl-ethyl)-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid
(2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (2-hydroxy-1-hydroxymethyl-2-phenyl-
ethyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (2-hydroxy-1-hydroxymethyl-2-phenyl-
ethyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-
carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;
4-[2-(1-Hydroxymethyl-cyclopropylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-
1-phenyl-ethyl)-amide;
4-[2-(2-Hydroxy-ethylamino)-5-methyl-pyrimidin-4-yl]-
1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-
amide;
4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-
1-phenyl-ethyl)-amide;
4-[2-(2-Hydroxy-propylamino)-5-methyl-pyrimidin-4-yl]-
1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-
amide;
4-[2-(2-Hydroxy-propylamino)-5-methyl-pyrimidin-4-yl]-
1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-
amide;
4-[2-(2-Hydroxy-cyclohexylamino)-5-methyl-pyrimidin-4-
yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-
ethyl)-amide;
4-(5-Hydroxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-
pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-
amide;
{ [4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
2-carbonyl]-amino }-phenyl-acetic acid methyl ester;
4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-
1-phenyl-ethyl)-amide;

Scb
A1

10071699-020802

4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;
4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;
4-(2-Ethylamino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-pyridin-3-yl-ethyl)-amide;
4-(2-Ethylamino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-ethyl]-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-phenyl)-2-hydroxy-ethyl]-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(2-fluoro-phenyl)-2-hydroxy-ethyl]-amide;
4-[2-(2-Cyclopropyl-1-hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(2,3-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Ethoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-[2-(1-Hydroxymethyl-2-methyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-oxo-1-phenyl-propyl)-amide;
4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;
4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;
4-[2-(2-Chloro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;
4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

Sub
A1

10071699-020802

4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(2-methoxy-phenyl)-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-(2-Methoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(2-Isopropoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2-Chloro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2,3-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-(2-Acetylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[5-Methyl-2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-{5-Methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-{5-Methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

Sub
A1

10071699-020802

N' - {4 - [5 - (2-Hydroxy-1-phenyl-ethylcarbamoyl) -1H-pyrrol-3-yl] -5-methyl-pyrimidin-2-yl} -hydrazinecarboxylic acid ethyl ester;

4 - {5-Methyl-2 - [(pyridin-3-ylmethyl) -amino] -pyrimidin-4-yl} -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - (2-Cyclopropylmethoxyamino-5-methyl-pyrimidin-4-yl) -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - [2 - (Isoxazol-3-ylamino) -5-methyl-pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - (2-Cyanoamino-5-methyl-pyrimidin-4-yl) -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - [2 - (2-Hydroxy-1-methyl-ethylamino) -5-methyl-pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl) -amide;

4 - (5-Methyl-2-o-tolylamino-pyrimidin-4-yl) -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl) -amide;

4 - (5-Methyl-2-o-tolylamino-pyrimidin-4-yl) -1H-pyrrole-2-carboxylic acid [1 - (3-chloro-phenyl) -2-hydroxy-ethyl] -amide;

4 - [2 - (2-Hydroxy-ethoxyamino) -5-methyl-pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - [2 - (N', N' -Dimethyl-hydrazino) -5-methyl-pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - [5-Methyl-2 - (2-trifluoromethyl-phenylamino) -pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - [5-Methyl-2 - (morpholin-4-ylamino) -pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - [5-Methyl-2 - (5-methyl-isoxazol-3-ylamino) -pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - {2 - [1 - (3-Chloro-4-fluoro-phenyl) -2-hydroxy-ethylamino] -5-methyl-pyrimidin-4-yl} -1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide;

4 - (5-Methyl-2-phenylamino-pyrimidin-4-yl) -1H-pyrrole-2-carboxylic acid [1 - (3-fluoro-phenyl) -2-hydroxy-ethyl] -amide;

4 - [2 - (1-Hydroxymethyl-propylamino) -5-methyl-pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid [1 - (3-chloro-phenyl) -2-hydroxy-ethyl] -amide;

4 - [2 - (2-Hydroxy-1-hydroxymethyl-ethylamino) -5-methyl-pyrimidin-4-yl] -1H-pyrrole-2-carboxylic acid [1 - (3-chloro-phenyl) -2-hydroxy-ethyl] -amide;

Sub
A1

10071699.020802

4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

4-[2-(2-Hydroxy-1-hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide; and

4-[5-Methyl-2-(2-methyl-cyclopropylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide.

41. A composition comprising a compound according to any of claims 20-40 and a pharmaceutically acceptable carrier.

42. The composition according to claim 41, further comprising an additional therapeutic agent.

43. A method of inhibiting ERK2, GSK-3, Aurora, CDK2, or Lck activity in a patient comprising the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

44. The method according to claim 43, wherein said method inhibits ERK2 activity in a patient.

45. A method of treating an ERK2-mediated disease in a patient in need thereof, said method comprising the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

46. The method according to claim 45, further comprising the step of administering to said patient an additional therapeutic agent.

5b
A1

10071699-020802

47. The method according to claim 45, wherein said disease is selected from cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), liver disease, pathologic immune conditions involving T cell activation, or CNS disorders.

48. The method according to claim 47, wherein the disease is cancer.

49. The method according to claim 48, wherein the disease is a cancer selected from breast; ovary; cervix; prostate; testis, genitourinary tract; esophagus; larynx, glioblastoma; neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma; bone; colon, adenoma; pancreas, adenocarcinoma; thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladder carcinoma; liver carcinoma and biliary passages; kidney carcinoma; myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine; colon-

Sub
A1

10071699.020802

rectum, large intestine, rectum; brain and central nervous system, or leukemia.

50. The method according to claim 45, wherein the disease is cardiovascular disease.

51. The method according to claim 50, wherein the disease is a cardiovascular disease selected from restenosis, cardiomegaly, arteriosclerosis, myocardial infarction, or congestive heart failure.

52. A method of treating a GSK-3-mediated disease in a patient in need thereof, said method comprising the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

53. The method according to claim 52, further comprising the step of administering to said patient an additional therapeutic agent.

54. The method according to claim 52, wherein said disease is diabetes.

55. The method according to claim 52, wherein said disease is Alzheimer's disease.

56. The method according to claim 52, wherein said disease is schizophrenia.

57. A method of enhancing glycogen synthesis in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically

Sub
A1

200020-66972002

Sub
A1

effective amount of the composition according to claim 41.

58. A method of lowering blood levels of glucose in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

59. A method of inhibiting the production of hyperphosphorylated Tau protein in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

60. A method of inhibiting the phosphorylation of β -catenin in a patient in need thereof, which method comprises the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

61. A method of treating an Aurora-2-mediated disease in a patient in need thereof, said method comprising the step of administering to said patient a therapeutically effective amount of the composition according to claim 41.

62. The method according to claim 61, further comprising the step of administering to said patient an additional therapeutic agent.

Sub
A1

10071699.020802

Sub
A1
63. The method according to claim 61, wherein said disease is selected from colon, breast, stomach, or ovarian cancer.

64. A method of treating CDK-2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a composition according to claim 41.

Sub
A1
10071699-020802
65. The method according to claim 64, wherein said disease is selected from cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, or an autoimmune disease.

66. A method of treating a Lck-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a composition according to claim 41.

67. The method according to claim 66, wherein said disease is selected from an autoimmune disease or transplant rejection.

Sub
A1
68. A method of inhibiting ERK2, Aurora-2, GSK-3, CDK-2, or Lck activity in a biological sample comprising the step of contacting said biological sample with a compound according to any one of claims 20-40.

69. A composition for coating an implantable device comprising a compound according to claim 20 and a carrier suitable for coating said implantable device.

Sub
A1

-187-

70. An implantable device coated with a composition
according to claim 69.

208020 669T 2007